- Bortezomib - the 1st proteasome inhibitor in clinical practise2004 | First Faculty of Medicine
- Bortezomib - the 1st proteasome inhibitor in clinical practisePublication without faculty affiliation
- The effect of new proteasome inhibitors, belactosin A and C, on protein metaoblism in isolated rat skeletal muscle2009 | Faculty of Medicine in Hradec Králové
- Bortezomib - the first proteasome inhibitor in clinical practise2003 | First Faculty of Medicine
- The Proteasome Inhibitor Bortezhomib (Velcade) in the Treatment of Relapsed/Refracotry Multiple Myeloma: The First Experience in the Czech Republic2005 | First Faculty of Medicine
- Proteasome inhibitors - New Option in the Treatment of Tumor Diseases2004 | First Faculty of Medicine
- The Proteasome Inhibitor Bortezomib (Velcade) in he Treatment of Relapsed/Refractory Multiple Myeloma. The First Experience in the Czech Republic2005 | First Faculty of Medicine
- The effect of proteasome inhibitor MLN273 on protein and amino acid metabolism in hyperhermia +1Publication without faculty affiliation
- Influence of proteasome inhibitors MG132 on protein metabolism in incubated rat skeletal musclePublication without faculty affiliation
- The first experience with bortezomib multiple myeloma therapy in Czech republic +1Publication without faculty affiliation
- The Proteasome Inhibitor Bortezhomib (Velcade) in the Treatment of Relapsed/Refracotry Multiple Myeloma: The First Experience in the Czech Republic +12005 | Faculty of Medicine in Hradec Králové
- Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma The First Experience in the Czech Republic2005 | First Faculty of Medicine
- Léčba mnohočetného myelomu2017 | First Faculty of Medicine
- Teplotním šokem proti mnohočetnému myelomu2020 | Faculty of Science
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)2023 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine
- The role of elotuzumab in the treatment of multiple myeloma2021 | First Faculty of Medicine
- Novinky v léčbě mnohočetného myelomu v roce 20172018 | First Faculty of Medicine
- Renální toxicita cílené léčby v onkologii2023 | First Faculty of Medicine
- New trends in the multiple myeloma treatment2019 | First Faculty of Medicine
- Elotuzumab in the treatment of multiple myeloma2020 | First Faculty of Medicine